We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-1.2%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$548M
AUM Growth
-$212M
Cap. Flow
-$139M
Cap. Flow %
-25.42%
Top 10 Hldgs %
37.58%
Holding
232
New
36
Increased
20
Reduced
48
Closed
92

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$11.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.51M
3
UTHR icon
United Therapeutics
UTHR
+$8.13M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.75M
5
ALT icon
Altimmune
ALT
+$5.53M

Top Sells

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$21M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$9.33M
3
SAGE
Sage Therapeutics
SAGE
+$8.38M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.11M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 43.2%
2 Technology 0.14%
3 Consumer Staples 0.03%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBIO icon
126
Mustang Bio
MBIO
$4.5M
$145K 0.03%
329
-400
-55% -$221K
TPST icon
127
Tempest Therapeutics
TPST
$13.8M
$132K 0.02%
4,756
– –
MITO
128
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$127K 0.02%
501,836
– –
BGMS
129
Bio Green Med Solution Inc
BGMS
$5.04M
$113K 0.02%
29
– –
LRMR icon
130
Larimar Therapeutics
LRMR
$398M
$100K 0.02%
51,606
– –
IVA
131
Inventiva
IVA
$1.09B
$93K 0.02%
15,579
– –
DRUG
132
Bright Minds Biosciences
DRUG
$732M
$86K 0.02%
21,192
– –
DFTX
133
Definium Therapeutics
DFTX
$5.91B
$68K 0.01%
7,064
– –
OVID icon
134
Ovid Therapeutics
OVID
$442M
$59K 0.01%
26,831
-711,541
-96% -$1.72M
ENVB icon
135
Enveric Biosciences
ENVB
$5.76M
$48K 0.01%
25
-22
-47% -$46.8K
CYTO
136
DELISTED
Altamira Therapeutics Ltd
CYTO
$36K 0.01%
188
-612
-77% -$198K
BXRX
137
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$3K ﹤0.01%
74
– –
ACAD icon
138
Acadia Pharmaceuticals
ACAD
$4.55B
– –
-1,882
Closed -$46K
ACET icon
139
CALL
Adicet Bio
ACET
$84.7M
– –
-3,881
Closed -$1.24M
ACRS icon
140
Aclaris Therapeutics
ACRS
$743M
– –
-12,124
Closed -$208K
AGEN
141
Agenus
AGEN
$329M
– –
-5,550
Closed -$267K
AKBA icon
142
CALL
Akebia Therapeutics
AKBA
$362M
– –
-800,000
Closed -$575K
AKBA icon
143
PUT
Akebia Therapeutics
AKBA
$362M
– –
-1,200,000
Closed -$860K
AMGN icon
144
Amgen
AMGN
$209B
– –
-20,000
Closed -$4.9M
ASMB icon
145
Assembly Biosciences
ASMB
$516M
– –
-18,923
Closed -$468K
ASND icon
146
Ascendis Pharma A/S
ASND
$16.5B
– –
-8,763
Closed -$1.03M
AUPH icon
147
Aurinia Pharmaceuticals
AUPH
$1.93B
– –
-87,071
Closed -$1.08M
AVTX icon
148
Avalo Therapeutics
AVTX
$1.03B
– –
-265
Closed -$554K
BCYC
149
CALL
Bicycle Therapeutics
BCYC
$280M
– –
-264,700
Closed -$11.6M
BCYC
150
Bicycle Therapeutics
BCYC
$280M
– –
-478,784
Closed -$21M
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Ikarian Capital held 232 positions worth $548M, down 28% from $760M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital withdrew a net $139M in Q2 2022, closing 92 positions and reducing 48 holdings. Its most notable exit was Bicycle Therapeutics, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in Esperion Therapeutics worth $13.1M.

  • Ikarian Capital's largest Q2 2022 buy was Esperion Therapeutics: 2,054,602 shares worth $13.1M.
  • Ikarian Capital added most to Alnylam Pharmaceuticals in Q2 2022, an estimated $8.51M increase.
  • Ikarian Capital's biggest Q2 2022 reduction was Adicet Bio, cutting an estimated $5M.
  • Ikarian Capital fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $21M.
  • Ikarian Capital's ten largest holdings make up 38% of its $548M portfolio in Q2 2022.
  • Ikarian Capital opened 36 new positions and closed 92 in Q2 2022.
  • Ikarian Capital's portfolio value fell 28% quarter-over-quarter to $548M.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.